Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Oct-Dec;36(4):255-60.
doi: 10.4103/0971-5851.171550.

Clinical profile and outcome of adult Hodgkin lymphoma: Experience from a tertiary care institution

Rahul Narayan Maddi  1 , Vijay Gandhi Linga  2 , Kalpathi Krishnamani Iyer  2 , Joseph Stalin Chowdary  2 , Sadashivudu Gundeti  2 , Raghunadharao Digumarti  3 , Tara Roshini Paul  4
Affiliations

Clinical profile and outcome of adult Hodgkin lymphoma: Experience from a tertiary care institution

Rahul Narayan Maddi et al. Indian J Med Paediatr Oncol. 2015 Oct-Dec.

Abstract

Treatment and outcome of Hodgkin lymphoma (HL) are the true success story of modern medicine. The data from the developing countries on long-term outcome of patients with HL is sparse.

Aims: Primary objective is to assess the progression-free survival (PFS). Secondary objective are overall survival (OS) and toxicities.

Settings and design: This is a retrospective analysis from the case records from a single institution.

Materials and methods: Institutional Ethical Committee approval was obtained. Between January 1991 and December 2010, 301 patients (age ≥18 years) underwent treatment at our institution.

Statistical analysis: Kaplan-Meyer curves were used to calculate the PFS and OS.

Results: The median age at presentation was 36 years, range from 19 to 75 years. The male to female ratio was 2.9:1. Seventy-five percent of patients had B symptoms. Majority presented in advanced stage (Stage III and IV) disease (64.7%). Mixed cellularity (74.4%) was the most common histology, followed by nodular sclerosis (13.9%). The most common chemotherapy regimen used was ABVD (61%).

Conclusions: Median follow-up of the cohort was 18.5 months (range 2-225). PFS and OS rate at 5 years is 66.3% and 79.7% respectively.

Keywords: Chemotherapy and toxicities; Hodgkin lymphoma; survival.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Progression free survival (months) for the entire cohort (n = 301)
Figure 2
Figure 2
Progression free survival (months) for early and advanced stage
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ansell SM. Hodgkin lymphoma: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol. 2012;87:1096–103. - PubMed
    1. Cerci JJ, Linardi CC, Pracchia LF, Junior JS, Trindade E, Delbeke D, et al. 2-[18F]-fluoro-2-desoxy-D-glucose positron emission tomography initial staging impacts on survival in Hodgkin lymphoma. World J Radiol. 2013;5:484–90. - PMC - PubMed
    1. Diehl V, Thomas RK, Re D. Part II: Hodgkin's lymphoma — Diagnosis and treatment. Lancet Oncol. 2004;5:19–26. - PubMed
    1. Armitage JO. Early-stage Hodgkin's lymphoma. N Engl J Med. 2010;363:653–62. - PubMed
    1. Pulte D, Jansen L, Gondos A, Emrich K, Holleczek B, Katalinic A, et al. Improved population level survival in younger Hodgkin lymphoma patients in Germany in the early 21 st century. Br J Haematol. 2014;164:851–7. - PubMed